Full text is available at the source.
Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
Chiglitazar reduces fatty liver disease caused by high-fat diet by affecting several body pathways in mice
AI simplified
Abstract
Chiglitazar significantly improved dyslipidemia and insulin resistance in mice with NAFLD.
- Chiglitazar was administered at doses of 5 mg/kg/d or 10 mg/kg/d to mice after 8 weeks on a high-fat diet.
- The treatment reduced hepatic steatosis, liver inflammation, and oxidative stress in the mice.
- RNA sequencing indicated that chiglitazar affected multiple biological pathways related to fatty acid metabolism and insulin signaling.
- The findings suggest that chiglitazar could be a potential therapeutic option for managing NAFLD.
AI simplified